Yellow Fever - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2016, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.

Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 5 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively for Yellow Fever.

Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Yellow Fever Overview 7
Therapeutics Development 8
Pipeline Products for Yellow Fever - Overview 8
Pipeline Products for Yellow Fever - Comparative Analysis 9
Yellow Fever - Therapeutics under Development by Companies 10
Yellow Fever - Therapeutics under Investigation by Universities/Institutes 11
Yellow Fever - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Yellow Fever - Products under Development by Companies 14
Yellow Fever - Products under Investigation by Universities/Institutes 15
Yellow Fever - Companies Involved in Therapeutics Development 16
Arno Therapeutics, Inc. 16
Bavarian Nordic A/S 17
BioCryst Pharmaceuticals, Inc. 18
Ennaid Therapeutics, LLC 19
iBio, Inc. 20
Johnson & Johnson 21
NewLink Genetics Corporation 22
Panacea Biotec Limited 23
Sihuan Pharmaceutical Holdings Group Ltd. 24
Valneva SE 25
Yellow Fever - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(arenavirus + yellow fever) vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AR-12 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BCX-4430 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DEF-201 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
FDX-000 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
JK-05 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RKP-00156 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Synthetic Peptides for Yellow Fever - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
XRX-001 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
yellow fever [strain YF17D] vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
yellow fever vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
yellow fever vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
yellow fever vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
yellow fever vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
yellow fever vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
yellow fever vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
yellow fever vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
yellow fever vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Yellow Fever - Dormant Projects 61
Yellow Fever - Product Development Milestones 62
Featured News & Press Releases 62
Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine 62
Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial 62
Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Yellow Fever, H2 2016 8
Number of Products under Development for Yellow Fever - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Yellow Fever - Pipeline by Arno Therapeutics, Inc., H2 2016 16
Yellow Fever - Pipeline by Bavarian Nordic A/S, H2 2016 17
Yellow Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016 18
Yellow Fever - Pipeline by Ennaid Therapeutics, LLC, H2 2016 19
Yellow Fever - Pipeline by iBio, Inc., H2 2016 20
Yellow Fever - Pipeline by Johnson & Johnson, H2 2016 21
Yellow Fever - Pipeline by NewLink Genetics Corporation, H2 2016 22
Yellow Fever - Pipeline by Panacea Biotec Limited, H2 2016 23
Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016 24
Yellow Fever - Pipeline by Valneva SE, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Yellow Fever - Dormant Projects, H2 2016 61